Cabaletta Bio to participate in upcoming investor conferences

PHILADELPHIA, Sept.

01, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc.

NASDAQ:CABA, a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced its participation in the fo…